阿比特龙治疗转移性去势抵抗性前列腺癌1 例

2009年9月至2014年12月在中南大学湘雅三医院泌尿外科收治1例转移性去势抵抗性前列腺癌(metastatic castration-resistant prostate cancer，mCRPC)患者，服用阿比特龙后，患者体能状态较好，疼痛较前稍缓解；复查结果示 总前列腺特异抗原(total prostate specific antigen，tPSA)、游离前列腺特异抗原(free prostate specific antigen，fPSA)明显降 低，tPSA暂波动在30~50 ng/mL，fPSA暂波动在10~20 ng/mL；复查MRI示肿瘤左侧外周带结节较前缩小；MRI及全身骨 扫描示骨转移较前无明显变化，未见明显新发病灶，提示阿比特龙治疗转移性去势抵抗性前列腺癌患者，不仅可显著 降低前列腺特异抗原(prostate specifi c antigen，PSA)水平，缩小肿瘤体积，而且明显减缓骨转移进展，减轻疼痛症状。

A case of metastatic castration-resistant prostate cancer by abiraterone treatment

We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. Aft er the treatment with abiraterone, patient’s performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or f PSA fluctuated between 30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.